A Study to Investigate Two Atteris Antimicrobial Products on Chronic Wound Healing.

Part 1 of this study will involve 5 patients with qualified chronic wounds which will receive
active treatment with both the Atteris Antimicrobial Skin and Wound Cleanser (AWC) and the
Atteris Antimicrobial Barrier Film Dressing (ABFD) for a 6-week period with a 12 week
follow-up in order to optimize the final study application protocols. Part 2 of this study is
a randomized, double blind, 2 by 2 factorial, controlled study comparing the AWC and/or the
ABFD with 100 research subjects and n=25 subjects per cell. Patients will be randomized to
receive either active AWC and active ABFD, or active AWD and placebo ABFD, or placebo AWC and
active ABFC, or AWC placebo and ABFD placebo in addition to standard of care (SOC). The
active AWC active ABFD versus AWC placebo ABFD placebo statistical contrast will be of most
importance and the clinical expectation is wounds treated with the active forms of these
products will heal faster than wounds treated with double placebo and this will additionally
provide data to power a future definitive study to compare the healing potential of the two
therapeutic modalities (AWC, ABFD).

Inclusion Criteria:

1. Male or female between the ages of 18 and 89

2. If IDDM or NIDDM, glycosylated hemoglobin, HgbA1c, ≤10%

3. Presence of chronic Wound of any etiology between 0.5 cm2 and 15 cm2, inclusive, post
debridement

4. Wound has been present for at least 4 weeks, but not greater than 52 weeks at time of
screening

5. Non-surgical wounds which meet the clinical definition of chronic between 0.5 cm2 and
15 cm2

6. Adequate arterial perfusion of the affected limb, defined as at least one of the
following:

1. Ankle-brachial index (ABI) ≥0.7 and ≤1.2

2. Dorsum transcutaneous oxygen test ≥ 30 mm Hg

3. Biphasic or triphasic Doppler waveforms at screening

7. Patient and/or caregiver have the ability and willingness to understand and comply
with study procedures and give written, informed consent prior to enrollment in the
study or initiation of study procedures.

Exclusion Criteria:

1. Suspected or confirmed signs/symptoms of active wound infection or gangrene

2. Hyperbaric Oxygen Therapy, any duration, within the past 12 months

3. Osteomyelitis

4. Use of oral or IV antibiotic/antimicrobial agents within 2 days (48 hours) of baseline

5. Subjects who have received growth factor therapy (e.g., autologous platelet-rich
plasma gel, becaplermin,) within 28 days of screening

6. Subjects who have received dermal substitutes (e.g. Integra, collagen, micronized
cadaver skin, bilayered cell therapy, dermal substitute, extracellular matrix etc.)
within 28 days of screening.

7. Pyoderma gangrenosum, or Reynaud's disease

8. Wound with necrotic tissue covered with slough or eschar that cannot be debrided

9. Chronic wounds with exposed bone

10. Wounds with fistulas or deep sinus tracks of unknown depth

11. Active Charcot foot on the study limb

12. Receiving hemodialysis or peritoneal dialysis

13. History of malignancy excluding non-melanoma skin cancer

14. Treatment with radiation or chemotherapy within 3 months of screening

15. Known immunosuppression, excluding diabetes mellitus

16. Receiving (within 30 days of enrollment) or scheduled to receive a medication or
treatment which is known to affect wound healing, such as systemic steroids (such as
daily prednisone), immunosuppressive therapy, radiation or chemotherapy of any kind,
autoimmune disease therapy or cytostatic therapy

17. Subjects with known alcohol or substance abuse within 6 months of screening

18. Subjects with known allergy to PHMB, acrylate polymer and silicone

19. Pregnancy or breastfeeding at time of screening

20. Participation in another investigational device, drug, or biological trial that may
interfere with results within 6 months of screening